GlassScriptPhysician profile
Cynthia E Duprey
NPI 1780026013
$3,109.77
in general payments reported to CMS, 2019-2025
35 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.79 · 2022: $506 · 2023: $546 · 2024: $748 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,389 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,389.49 |
| Education | $176.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $453.59 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $303.98 | 2023-2025 | Calquence, Enhertu, Lynparza |
| Pfizer INC. | $290.18 | 2021-2025 | |
| Daiichi Sankyo INC. | $228.52 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Karyopharm Therapeutics INC. | $164.76 | 2022-2025 | Xpovio |
| Seagen INC. | $143.17 | 2022-2023 | Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $128.62 | 2022-2025 | |
| Glaxosmithkline, LLC. | $127.68 | 2022-2024 | Ojjaara, Shingrix, Jemperli |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Abbvie INC. | $117.66 | 2024-2025 | |
| Genentech USA, INC. | $107.10 | 2023 | Lunsumio |
| Impel Pharmaceuticals INC. | $102.97 | 2023 | Trudhesa |
| Amgen INC. | $80.93 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $79.65 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $78.91 | 2025 | Keytruda, Keytruda Qlex, Welireg |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $73.42 | 2022 | |
| Eisai INC. | $66.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.31 | 2025 | Ninlaro |
| Lilly USA, LLC | $51.64 | 2025 | Jaypirca, Verzenio |
| Pharmaessentia USA Corporation | $32.28 | 2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $24.62 | 2025 | |
| Dendreon Pharmaceuticals LLC | $23.33 | 2025 | Provenge |
| Celgene Corporation | $22.84 | 2022 | |
| Sobi, INC | $21.58 | 2022 | |
| Syndax Pharmaceuticals, INC. | $20.83 | 2025 | |
| Coherus Oncology, INC. | $20.54 | 2025 | Loqtorzi |
| Adc Therapeutics America, INC. | $20.53 | 2024 | |
| Sumitomo Pharma America, INC. | $20.45 | 2025 | Orgovyx |
| Beone Medicines USA, INC. | $20.21 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $20.04 | 2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $19.94 | 2024 | Rezlidhia, Tavalisse |
| Stemline Therapeutics INC. | $18.63 | 2023 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $17.69 | 2024 | |
| Exelixis INC. | $15.79 | 2023 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Duprey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.